Abstracts tagged "Treg cells"

Abstract Number: 1845 • ACR Convergence 2024
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Amy Anderson¹, Luke Jones², Fiona Rayner³, Jessica Swift¹, Daniel Maunder¹, Henrique de Paula Lemos¹, David Swan⁴, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Gary Reynolds¹, Jasmine Sim¹, Andrew Melville⁵, Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Karim Raza⁷, Christopher Buckley⁸, Kenneth Baker¹, Arthur Pratt³, Andrew Filer⁷ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
Abstract Number: 1846 • ACR Convergence 2024
Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Amy Anderson¹, Henrique de Paula Lemos¹, Hendrik Nel², Sofia Sorbet Santiago¹, Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville⁴, Stefan Siebert⁴, Iain McInnes⁵, Carl Goodyear⁴, Catharien Hilkens¹, Andrew Filer⁶, Karim Raza⁶, Christopher Buckley⁷, Hugh Reid⁸, Kenneth Baker¹, Arthur Pratt³, Jamie Rossjohn⁸, Ranjeny Thomas⁹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁶Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁷Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
Abstract Number: 1848 • ACR Convergence 2024
Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis
Vallayyachari Kommoju¹, Sree Nethra Bulusu², Shruthi S Vembar³, Chengappa Kavadichanda⁴, Molly Thabah⁵, Christina Mary Mariaselvam² and Vir Singh Negi⁶, ¹JIPMER, Pondicherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³IGIB, Bengalore, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Inflammatory cytokines in the periphery can affect Treg stability and function by altering its molecular signatures. We aimed to characterize Treg phenotype, function and…
Abstract Number: 1852 • ACR Convergence 2024
Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus
Grace Crossland¹, Lindsay Mendyka², Kaitlyn Dowling³, Michael Constantinides⁴ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Dartmouth College, Lebanon, NH, ⁴Scripps Research Institute, San Diego, CA
Background/Purpose: Approximately 80% of cutaneous lupus erythematosus (CLE) patients experience sensitivity to ultraviolet (UV) sunlight rays, which leads to disfiguring skin lesions or systemic disease…
Abstract Number: 1864 • ACR Convergence 2024
S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Julia Manasson¹, Marisella Panduro², Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: The dysregulation of immune checkpoint receptors on T cells and antigen presenting cells (APCs) drives autoimmunity while receptor agonism is expected to restore immune…
Abstract Number: 2632 • ACR Convergence 2024
Genetically-engineered Ro-specific Regulatory T Cells to Treat Primary Sjögren’s Disease
Zhi Feng sherman Lim¹, Yi Tian Ting¹, Fabien Vincent², Maureen Rischmueller³, Eric Morand⁴ and Joshua Ooi¹, ¹Monash University-T Cell Therapies Research Group, Clayton, Victoria, Australia, ²Monash University, Clayton, Victoria, Australia, ³RheumatologySA, Adelaide, Australia, ⁴School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Autoantigen-specific regulatory T cells (Tregs) are potent, and specific, suppressors of pathogenic autoimmunity, and can be harnessed to treat autoimmune disease. In primary Sjögren’s…
Abstract Number: 0092 • ACR Convergence 2024
A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Hulya Bukulmez¹, Adrienne Dennis², kristine Highland³ and Steven N. Emancipator⁴, ¹MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, ²MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH
Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
Abstract Number: 0514 • ACR Convergence 2024
Efficacy, Safety and Mechanism of Butyrate in the Treatment of Rheumatoid Arthritis (RA)
Jing He¹, Naidi Wang², Yuhui Li³, Ruoyi Wang², Xiao Tan², Runzhi Zhufeng², Yipeng Han², Hao Li², Yuebo Jin² and Zhanguo Li⁴, ¹Rheumatology, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ³Peking University, BeiJing, China, ⁴People’s Hospital Peking University Health Sciences Centre, Beijing, China
Background/Purpose: This study aims to investigate the safety and efficacy of butyrate capsules in treating patients with rheumatoid arthritis (RA) and elucidate the underlying mechanisms.Methods:…
Abstract Number: 0874 • ACR Convergence 2024
Defining a Protective Role for Mucosal-associated Invariant T (MAIT) Cells in Spontaneous Cutaneous Lupus Erythematosus
Grace Crossland¹, Lindsay Mendyka², Michael Constantinides³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Scripps Research Institute, San Diego, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death in young females, and 70-85% of patients experience skin disease (cutaneous LE, CLE). The…
Abstract Number: 0875 • ACR Convergence 2024
Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Daniel Patton, Alex Chen, Justin Bowser, Kaelen Encarnacion, Jennifer Gardell, Emily Gilbertson, Susan Julien, Meghan Maurer, Brent Meengs, Nadine Morgan, Allison O'Rourke, Cong Tan, Jon Therriault, Kristine Swiderek and Courtney Crane, Mozart Therapeutics, Seattle, WA
Background/Purpose: CD8 Treg, characterized in human peripheral blood mononuclear cells (PBMC) by expression of inhibitory killer immunoglobulin receptors (KIRs), regulate immune balance by eliminating self-reactive…
Abstract Number: 1797 • ACR Convergence 2024
Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis
Carol Nassar¹, Rene Quevedo², M. Teresa Ciudad², Zoha Faheem³, Kieran Manion⁴, Carolina Munoz-Grajales⁵, Michael Kim⁶, Dafna Gladman⁷, Murray Urowitz⁸, Zahi Touma¹, Tracy McGaha⁹ and Joan Wither⁶, ¹University of Toronto, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵UHN/TWH, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Self employed, Toronto, ON, Canada, ⁹University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
Abstract Number: 1835 • ACR Convergence 2024
FoxP3Hi CTLA4+ ICOS+ Regulatory T Cells Are Expanded in Patients with Sarcoidosis but Not Systemic Sclerosis or IgG4-Related Disease
Laura Yockey¹, Thomas Guy², Chinmay Gadiraju³, Ian Doyle¹, Jesse Akaa⁴, Alison Puri⁵, Zachary Wallace⁶, Guy Katz¹, Sydney Montesi¹, John Stone⁷, Flavia Castelino¹, Shiv Pillai⁸, Andrew Luster⁹, Vinay Mahajan³ and Cory Perugino¹, ¹Massachusetts General Hospital, Boston, MA, ²Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachussets General Hospital, Boston, MA, ⁵Boston University, Brookline, MA, ⁶Massachusetts General Hospital, Newton, MA, ⁷Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁸Harvard Medical School, Cambridge, MA, ⁹Massachusetts General Hospital, Charlestown, MA
Background/Purpose: The absence of regulatory T cells (Tregs) results in multiorgan autoimmunity in the context of monogenic “Tregopathies”, but their role in mediating polygenic autoimmune…
Abstract Number: 0799 • ACR Convergence 2023
Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus
Holly Wobma¹, Xianliang Rui², Francesca Alvarez-Calderon², Ulrike Gerdemann², Connor McGuckin², Bruce Blazar³, Victor Tkachev⁴ and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Division of Pediatric Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, ⁴Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
Background/Purpose: Chimeric Antigen Receptor Regulatory T cells (CAR-Tregs) are an emerging strategy to restore immune tolerance during auto- or allo-immune conditions. However, most autoimmune diseases…
Abstract Number: 0887 • ACR Convergence 2023
Dapagliflozin Modulates Inflammation and Germinal Centers in Lupus by Increasing Regulatory T Cells
Javier Rangel-Moreno¹, Maria de la Luz Garcia-Hernandez², Mary O'Connell³, Daria Krenitsky⁴, Maria Fernanda Ossa-Echeverri¹, Mark Lusco⁵, John Looney⁶ and Jennifer Anolik³, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Division of Allergy, Immunology and Rheumatology/University of Rochester Medical Center, Rochester, NY, ⁵Department of Pathology and Laboratory Medicine/University of Rochester, Rochester, NY, ⁶Division of Allergy, Immunology and Rheumtology, Rochester, NY
Background/Purpose: Nephritis is one of the most severe manifestations of lupus, affecting 40-70% of patients. Though immune-targeted therapies have improved, a significant number of patients…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].